HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.058503v1 50/5/703    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Otsuka, T. Articles by Farde, L. Search for Related Content PubMed PubMed Citation Articles by Otsuka, T. Articles by Farde, L.

Quantitative PET Analysis of the Dopamine D₂ Receptor Agonist Radioligand ¹¹C-(R)-2-CH₃O-N-n-Propylnorapomorphine in the Human Brain

¹ Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan; ² Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan; ³ Psychiatry Section, Department of Clinical Neuroscience, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden; and ⁴ Molecular Probe Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

Correspondence: For correspondence or reprints contact: Hiroshi Ito, Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences 4-9-1, Anagawa, Inage-ku, Chiba, 263-8555, Japan. E-mail: hito{at}nirs.go.jp

It has been demonstrated in vitro that the dopamine D₂ receptor has 2 interconvertible affinity states for endogenous dopamine, referred to as the high- and the low-affinity states. ¹¹C-(R)-2-CH₃O-N-n-propylnorapomorphine (¹¹C-MNPA) is a new agonist radioligand for in vivo imaging of the high-affinity state of dopamine D₂ receptors using PET. In the present study, the kinetics of ¹¹C-MNPA were examined for the first time, to our knowledge, in the human brain and analyzed using quantitative approaches with or without an arterial input function. Methods: A 90-min dynamic PET scan was obtained for 10 healthy men after an intravenous injection of ¹¹C-MNPA. The binding potential (BP_ND) was calculated using the indirect kinetic method, a kinetic compartment analysis with a metabolite-corrected arterial input function. BP_ND was also calculated by the simplified reference tissue model (SRTM) and transient equilibrium methods, both with the cerebellum as the reference brain region. The results of the quantitative methods were compared in a cross-validation approach. Results: The highest regional radioactivity was observed in the putamen. BP_ND values obtained by kinetic analysis were 0.82 ± 0.09, 0.59 ± 0.11, and 0.28 ± 0.06, respectively, in the putamen, caudate, and thalamus. BP_ND values obtained by the SRTM and transient equilibrium methods were in good agreement with those obtained by the indirect kinetic method (r = 0.98 and r = 0.93, respectively). For all quantification methods, the BP_ND values based on data acquired from 0 to 60 min were in good agreement with those based on data acquired from 0 to 90 min (r = 0.90–0.99). Conclusion: The regional distribution of ¹¹C-MNPA binding was in good agreement with previous PET studies of dopamine D₂ receptors in the human brain using antagonist radioligands. The results support routine use of the SRTM and transient equilibrium methods, that is, methods that do not require an arterial input function and need a scan time of only about 60 min. ¹¹C-MNPA should thus be useful for clinical research on the pathophysiology of neuropsychiatric disorders and estimation of dopamine D₂ receptor occupancy by dopaminergic drugs.

Key Words: ¹¹C-MNPA • agonist • dopamine D₂ receptor • positron emission tomography • human

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]